Clinical Trials Directory

Trials / Conditions / Cat Allergy

Cat Allergy

20 registered clinical trials studyying Cat Allergy1 currently recruiting.

StatusTrialSponsorPhase
RecruitingViral Mucosal Reprogramming
NCT05331170
The University of Texas Medical Branch, GalvestonPhase 2
CompletedEffectiveness of an Air Purifier on Asthmatic and Cat-allergic Subjects in the ALYATEC Environmental Exposure
NCT06691568
Dyson Technology LtdN/A
CompletedDiagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy
NCT04435678
MacroArray Diagnostics GmbHN/A
CompletedStudy in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduc
NCT03838731
Regeneron PharmaceuticalsPhase 2
TerminatedEvaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients
NCT02959073
University of Zurich
CompletedA Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
NCT02311413
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
CompletedAnti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat All
NCT02237196
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1 / Phase 2
CompletedEvaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients
NCT02399579
University of ZurichN/A
CompletedPhase III Cat-PAD Follow-on Study
NCT02040844
Circassia LimitedPhase 3
CompletedAn Optional Two Year Follow Up Study to Study CP005A
NCT01604018
Circassia Limited
CompletedIdentification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
NCT01383590
Circassia LimitedPhase 1
CompletedIdentification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
NCT01383603
Circassia LimitedPhase 1
TerminatedSafety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Al
NCT01292070
National Institute of Allergy and Infectious Diseases (NIAID)EARLY_Phase 1
CompletedCat-PAD Follow on Study
NCT01272323
Circassia Limited
CompletedCat-PAD Exposure Chamber Study
NCT01033344
Circassia LimitedPhase 2
CompletedThe Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
NCT01003301
Johns Hopkins UniversityPhase 2
CompletedExposure Chamber Trial With Cat Immunotherapy
NCT00987909
ALK-Abelló A/SPhase 2
CompletedSafety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
NCT00867906
Circassia LimitedPhase 2
CompletedEffectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
NCT00729508
Circassia LimitedPhase 2
CompletedSafety of Cat-PAD in Cat Allergic Subjects
NCT00685711
Circassia LimitedPhase 1 / Phase 2